Compare AbbVie Inc (ABBV) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Williams-Sonoma, Inc. — how do they compare? AbbVie Inc trades at $249.77 (market cap $441.94B), while Williams-Sonoma, Inc. trades at $244.93 (market cap $29.51B). The key difference: AbbVie Inc is far larger — about 15× Williams-Sonoma, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | WSM | |
|---|---|---|
Market Cap | $441.94B | $29.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $251.81 |
52-Week Low | $197.38 | $168.64 |
Enterprise Value | $506.19B | $30.35B |
Dividend Yield | 2.77% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Williams-Sonoma (WSM) trades at $250.82, down 0.39% on the day, with strong profitability metrics including a 13.81% net income margin and 54.01% ROE. The stock shows a bullish technical trend, supported by moving averages, but RSI levels indicate overbought conditions. Recent earnings beats and a solid dividend history highlight operational strength, though valuation ratios like P/E of 28.09 suggest premium pricing. News coverage remains active, focusing on earnings potential and competitive positioning in the home furnishings sector.
WSM presents a mixed outlook: robust fundamentals and consistent earnings beats support upside, but high valuation and technical overbought signals pose near-term risks. Investor sentiment is cautiously optimistic, with a Moderate Buy analyst consensus and a $231.10 price target slightly below current levels. Key risks include consumer discretionary volatility and competitive pressures, while institutional interest and dividend payments offer stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
